[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Completed

Conditions studied: Retrospective Study, Glioma, Brain Neoplasms

In brief

This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).

Key facts

Study ID

NCT07238322

Run by

Telix Pharmaceuticals (Innovations) Pty Limited

People needed

253

Starts

2025-09-22

Expected to finish

2026-01-23

Last updated by the study team

2026-05-15

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed patient informed consent with secondary use of data permitted. Pediatric patients (<18 years of age) will provide assent along with parental/legal guardian /caregiver consent
• Male or Female of any age at the time of [18F]FET PET imaging. While there is no age restriction, it is expected that enrollment of patients ≤ 3 years old will be rare due to the very low incidence of glioma in this age group.
• Documented histologic diagnosis or clinical suspicion of glioma (Grades 1-4) based on local clinical assessment.
• Underwent [18F]FET PET imaging as part of routine clinical care after completion of primary treatment (surgery, radiation therapy, and/or chemotherapy).
• Evidence of radiographic suspicion of recurrence or progression on MRI at the time of [18F]FET PET imaging.
• The adult patient, 18 years of age or older, has received nominal injected dose of 4 to 7 mCi (148 - 259 MBq ) of [18F]FET per imaging time point.
• The pediatric patients, 0-17 years old, must have received a pediatric dose adjusted based upon the patient's body weight.

You may not qualify if…

• Participants will be excluded if they did not meet any of the inclusion criteria or institutional requirements for participation.
• Did not meet all inclusion criteria.
• Did not undergo [18F]FET PET imaging as part of routine clinical care.
• Imaging data or associated clinical information is incomplete, non-evaluable, or of insufficient quality for analysis.
• Any institutional or regulatory requirement that precludes data sharing or inclusion in retrospective research studies.

Where it is running

• University of California, San Francisco — San Francisco, California, United States
• University Hospital Essen — Essen, Germany
• Universityhospital Tuebingen — Tübingen, Germany
• The University Medical Center Utrecht — Utrecht, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.